











FINANCIAL PROTECTION AND IMPROVED ACCESS TO HEALTH CARE: PEER-TO-PEER LEARNING WORKSHOP FINDING SOLUTIONS TO COMMON CHALLENGES FEBRUARY 15-19, 2016 ACCRA, GHANA

Day II, Session V.









to Pharmaceuticals and Services

(PHT)

Kwesi E Eghan, SIAPS Program

Learning Objectives

- Coverage of Medicines. Understand how countries have selected drugs to be covered under their medicines benefit packages
- Management of Pharmaceuticals. Learn how countries have successfully managed pharmaceuticals- a driver of UHC program expenditures
- Threats to Access. Understand the threats to achieving access to medicines benefits
- Design of Medicines Benefits. Explore best practices for designing medicines benefits



Why Focus on Medicines?

- Medicines save lives and improve health, but they can be costly to health systems, and can impoverish individuals and can impove is a simple of the costly to health systems.
- Between 20% and 60% of health expenditures in LMICs goes to medicines^b
- In low- to middle-income countries (LMICs), up to 80% to 90% of medicines are purchased out-of-pocket as opposed to being paid for by health insurance schemes
- Problems with access—average availability of selected generic medicines in LMICs:
 - Public sector less than 42%
 - Private sector almost 72

a Managing Access to Medicines and Health Technologies, MSH B WHO 2010



Medicines Account for 3 out of 10 Sources of Inefficiencies in Health Systems

Sources of Inefficiencies^a

- Underuse of generic medicines and overuse of brand medicines
- Use of substandard and counterfeit medicines
- Inappropriate or ineffective use.
- Overuse or supply of equipment, investigations, and procedures.
- Inappropriate or costly staff
 mix, unmotivated workers


Inefficiencies account for

30%-40%

of all health expenditures



Access to Essential Medicines and UHCa



a WHO



Universal Health Coverage-Benefit Package Definitions

A medicines benefit program is a component of the UHC Benefit Package that covers some or all medicines prescribed and dispensed to beneficiaries. It is drawn after the minimum or optimal health benefit package is defined.^a

Medicine Benefits Management is the set of rules, controls, and enforcement tools that define how eligible beneficiaries can obtain payment for prescription medicines under a public budget or funded health care program.^b



Medicines Benefits Design Key Considerations

Static components (although regularly updated)

Dynamic processes

Reimbursement list: which medicines are covered

Reimbursement rates, prices, discounts, budget caps, etc.

Patient eligibility (subpopulation, condition, age, gender, etc.) Patient copayment: exemptions, limits

Set information systems to capture data

Compensation for distributor, pharmacist;

Assessment and decision making on inclusion of new technologies


Case management for high-cost patients

Negotiation strategies for deals with industry





Coverage and Medicines Cost in Ghana




Source: Roberts and Reich, 2011, data from Mensah and Acheampong 2009





How the Insurance System Interacts with the Pharmaceutical System







Addressing cost through appropriate Medicines Supply Management

Selection

- Burden of disease
- Effectiveness
- Safety and quality
- Appropriateness

Procurement

Procurement strategy must appreciate the risk of stock-outs and mitigate against this risk

Costing and Financing

- Estimate likely medicine consumption over the period.
- Explore price volume arrangements with suppliers in the face of volume uncertainty
- Manage the risk of currency fluctuation and changes in the input costs that may affect suppliers



How Health Technology Assessment is Used for Selection of Medicines

lealth Systems

Fragile states
HTA Focus:
Essential
services and
emergency
kits

Low income countries with low coverage HTA Focus: Primary health care packages

Middle income countries with low coverage HTA Focus: Guaranteed packages of care

health
systems

HTA
Focus:
Marginal
analysis
for
additions
to
packages

Strong

Continuum of HTA Activities





Pricing and Reimbursement of Dispensers

Approaches


- Internal or External Reference Pricing
- Single Exit Pricing
- Traditional Margin or Mark-Up Pricing

Mechanisms

- Fee for Services
 Risk of over-servicing, no incentive not to dispense medicine, rewards process rather than outcomes
- Case-Based
 Less incentive to over-service, no incentive not to dispense, some opportunity to reward outcomes.
- Capitation
 No incentive to over-service




Ghana Medicines Benefits Program







How Computers can Improve Efficiency of Claims Management for Medicines



Reporting

- Utilisation management
- Clinical management
- Pricing management
- Reference pricing
- Formulary
- Benefit management

Funder—Private insurance or government





Managing cost by Analyzing Routine Pharmaceutical Monitoring Indicators

Performance Measures	 Cost Utilization Quality of care Adherence
Cost	 Avg. cost per member per month (PMPM) Avg. net cost per dispensing per month
Utilization	 Avg. no. of dispensings PMPM Total no. of dispensings per therapeutic class
Quality of Care	 % of patients with ARI receiving antibiotics % of patients discharged from hospital with acute myocardial infarction receiving beta blockers
Fraud, Abuse	 No. of prescriptions of opioids per provider No. of dispensings per member SIAPS

Achieving UHC and Access to Medicines Requires Balancing Competing Objectives

Ensure Availability of
Quality Products
both generic
and novel products

33 66

Improve
Equitable Access
particularly for the poor and near-poor

Appropriate Use
of needed, safe, and
effective medicines taken
properly

Keep Costs
Affordable
for households and health system





Examples of Active Interventions



South African and Namibia—

Pricing introduced at regulator level.

Price = single exit price + logistics fee + dispensing fee (dispensing fee varies with cost of medicine).





China—Reimbursed patients only for medicines listed on the formulary, capped hospital revenue from medicine sales, and raised provider service fees.



South Korea—

Separated prescribing and dispensing services.





Common Threats to Achieving Access to Medicines Benefits

- Inability to manage competing political and policy goals
- Inappropriate benefit design
- Inefficient use of resources.
- Absence of efficient data systems and human capacity to generate information.

- Failure to routinely monitor benefit policy effects on access, use, health
- Failure to adapt technology to assist in adjudication of medicines claims
- Failure to adapt policies to changing system context
- Failure to communicate with public, patients, providers
- Failure to negotiate with industry, and suppliers

Best Practices in Designing Medicines Benefits

- "Smart" therapeutics—inpatient and outpatient medicines coverage of essential medicines, medicines on clinical guidelines
- *Increased efficiency*—appropriate generic/therapeutic substitution, efficient procurement and distribution systems
- Introduction of disease management program for chronic disease and coverage of high cost medicines
- Reliable partners—accredited health providers and dispensing outlets, competitive sourcing from quality assured suppliers
- Performance management—robust management systems for inventory management, claims management and drug use review, fraud detection
- Patient, provider, public education—on UHC, medicines, value
- Culture of adaption—routine monitoring, evaluating, learning
- Revise benefits -- Make appropriate decisions using a carve-in or carve-out approach

THANK YOU



